Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy.
Heyns
C F
CF
Department of Urology, University of Stellenbosch and Tygerberg Hospital, South Africa. Electronic address: cfh2@sun.ac.za.
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015536:Down-Regulation; D042241:Early Diagnosis; D006801:Humans; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D013997:Time Factors; D017211:Treatment Failure
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen